• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.埃博拉疫苗。水疱性口炎病毒载体埃博拉疫苗（VSV-EBOV）能迅速保护猕猴免受2014/15年埃博拉病毒爆发毒株的感染。
Science. 2015 Aug 14;349(6249):739-42. doi: 10.1126/science.aab3920. Epub 2015 Aug 6.
2
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.VSV-EBOV 疫苗接种诱导的抗病毒先天免疫反应有助于快速保护。
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
3
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.单价三价囊泡疫苗可保护猕猴免受致命埃博拉病毒和马尔堡病毒的挑战。
J Virol. 2018 Jan 17;92(3). doi: 10.1128/JVI.01190-17. Print 2018 Feb 1.
4
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.水疱性口炎病毒-埃博拉病毒暴露后治疗对感染马科纳埃博拉病毒的恒河猴的疗效。
J Infect Dis. 2016 Oct 15;214(suppl 3):S360-S366. doi: 10.1093/infdis/jiw218. Epub 2016 Aug 5.
5
Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.单次低剂量 VSV-EBOV 疫苗接种可保护食蟹猴免受致命性埃博拉病毒挑战。
EBioMedicine. 2019 Nov;49:223-231. doi: 10.1016/j.ebiom.2019.09.055. Epub 2019 Oct 17.
6
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.用高度减毒的重组水疱性口炎病毒载体进行疫苗接种可抵御致死剂量埃博拉病毒的攻击。
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.
7
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.一种表达埃博拉病毒变体马科纳糖蛋白的腺病毒疫苗在豚鼠和非人灵长类动物中具有有效性。
J Infect Dis. 2016 Oct 15;214(suppl 3):S326-S332. doi: 10.1093/infdis/jiw250. Epub 2016 Aug 4.
8
Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.经鼻内接种表达埃博拉病毒糖蛋白GP的减毒1型人副流感病毒在非洲绿猴中具有免疫原性。
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02469-16. Print 2017 May 15.
9
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.基于水疱性口炎病毒的疫苗可保护非人灵长类动物免受本迪布焦埃博拉病毒感染。
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.
10
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.单剂量减毒水泡性口炎病毒疫苗可保护灵长类动物免受埃博拉马科纳病毒感染。
Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

引用本文的文献

1
Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein.使用mRNA和rVSV平台的同源和异源疫苗接种方案可诱导针对发热伴血小板减少综合征病毒糖蛋白的强效免疫反应。
Viruses. 2025 Aug 8;17(8):1095. doi: 10.3390/v17081095.
2
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge.单剂量基于水疱性口炎病毒的疫苗可保护小鼠免受致死性异源克里米亚-刚果出血热病毒攻击。
NPJ Vaccines. 2025 May 30;10(1):109. doi: 10.1038/s41541-025-01164-3.
3
Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease.单剂量复制子RNA苏丹病毒疫苗能一致地保护雌性豚鼠免受疾病侵害。
Nat Commun. 2025 May 6;16(1):4199. doi: 10.1038/s41467-025-59560-1.
4
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.一种具有复制能力的基于水疱性口炎病毒的拉沙病毒候选疫苗的临床前开发已推进到人体临床试验阶段。
EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28.
5
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.rVSVΔG-ZEBOV-GP疫苗在非人灵长类埃博拉病毒攻击模型中的广泛剂量范围内具有高度免疫原性且有效。
Viruses. 2025 Feb 28;17(3):341. doi: 10.3390/v17030341.
6
Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.rVSV∆G-ZEBOV-GP疫苗在非人灵长类埃博拉病毒攻击模型中的免疫原性持久性及保护作用
Viruses. 2025 Feb 28;17(3):342. doi: 10.3390/v17030342.
7
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.口服药物瑞德西韦可保护非人灵长类动物免受致命埃博拉病毒感染。
Sci Adv. 2025 Mar 14;11(11):eadw0659. doi: 10.1126/sciadv.adw0659.
8
Filovirus vaccines as a response paradigm for emerging infectious diseases.丝状病毒疫苗作为新兴传染病的应对范例。
NPJ Vaccines. 2024 Oct 11;9(1):186. doi: 10.1038/s41541-024-00985-y.
9
A fatty acid-ordered plasma membrane environment is critical for Ebola virus matrix protein assembly and budding.脂肪酸有序的质膜环境对于埃博拉病毒基质蛋白组装和出芽至关重要。
J Lipid Res. 2024 Nov;65(11):100663. doi: 10.1016/j.jlr.2024.100663. Epub 2024 Oct 5.
10
Improved thermal stabilization of VSV-vector with enhanced vacuum drying in pullulan and trehalose-based films.用普鲁兰和海藻糖基膜增强真空干燥提高 VSV 载体的热稳定性。
Sci Rep. 2024 Aug 9;14(1):18522. doi: 10.1038/s41598-024-69003-4.

本文引用的文献

1
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.单剂量减毒水泡性口炎病毒疫苗可保护灵长类动物免受埃博拉马科纳病毒感染。
Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.
2
Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences.病毒学。来自马里病例序列的埃博拉病毒的突变率和基因型变异
Science. 2015 Apr 3;348(6230):117-9. doi: 10.1126/science.aaa5646. Epub 2015 Mar 26.
3
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.针刺伤后使用水疱性口炎病毒载体埃博拉疫苗进行紧急暴露后接种。
JAMA. 2015;313(12):1249-55. doi: 10.1001/jama.2015.1995.
4
Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak.基因组监测解析了 2014 年埃博拉疫情期间病毒的起源和传播。
Science. 2014 Sep 12;345(6202):1369-72. doi: 10.1126/science.1259657. Epub 2014 Aug 28.
5
Emergence of Zaire Ebola virus disease in Guinea.刚果（金）埃博拉疫情在几内亚出现。
N Engl J Med. 2014 Oct 9;371(15):1418-25. doi: 10.1056/NEJMoa1404505. Epub 2014 Apr 16.
6
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.抗体对于 rVSV/ZEBOV-GP 介导的非人类灵长类动物抵抗致死性埃博拉病毒攻击的保护是必要的。
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.
7
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.德国汉堡生物安全 4 级实验室中埃博拉病毒意外暴露的管理。
J Infect Dis. 2011 Nov;204 Suppl 3:S785-90. doi: 10.1093/infdis/jir298.
8
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.基于重组水疱性口炎病毒的埃博拉和马尔堡病毒感染疫苗。
J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1075-81. doi: 10.1093/infdis/jir349.
9
Ebola haemorrhagic fever.埃博拉出血热。
Lancet. 2011 Mar 5;377(9768):849-62. doi: 10.1016/S0140-6736(10)60667-8.
10
Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.埃博拉病毒 VP24 与核转运蛋白的结合对于抑制干扰素信号是必需的。
J Virol. 2010 Jan;84(2):1169-75. doi: 10.1128/JVI.01372-09. Epub 2009 Nov 4.

埃博拉疫苗。水疱性口炎病毒载体埃博拉疫苗（VSV-EBOV）能迅速保护猕猴免受2014/15年埃博拉病毒爆发毒株的感染。

EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.

作者信息

Marzi Andrea, Robertson Shelly J, Haddock Elaine, Feldmann Friederike, Hanley Patrick W, Scott Dana P, Strong James E, Kobinger Gary, Best Sonja M, Feldmann Heinz

机构信息

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.

Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.

出版信息

Science. 2015 Aug 14;349(6249):739-42. doi: 10.1126/science.aab3920. Epub 2015 Aug 6.

DOI:10.1126/science.aab3920
PMID:26249231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11040598/
Abstract

The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.

摘要

最新的埃博拉病毒（EBOV）疫情在几内亚、塞拉利昂和利比里亚迅速蔓延，引发了全球公共卫生危机，并加速了对临床试验中实验性治疗方法和疫苗的评估。其中一种疫苗基于表达EBOV糖蛋白的重组水疱性口炎病毒（VSV-EBOV），这是一种具有显著临床前疗效的减毒活载体。在此，我们提供临床前证据，证明VSV-EBOV能完全保护猕猴免受西非EBOV-Makona毒株的致死性攻击。分别在攻击前7天和3天给予单剂量疫苗，可实现完全和部分保护。这表明VSV-EBOV可能以相对较短的免疫时间保护人类免受西非EBOV感染，从而促进其用于即时的公共卫生应对。